- $13.27m
- -$23.40m
Annual balance sheet for Athira Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 185 | 254 | 200 | 147 | 51.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.3 | 2.34 | 1.23 | 1.63 | 0 |
| Prepaid Expenses | |||||
| Total Current Assets | 192 | 261 | 208 | 155 | 54.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.58 | 5.22 | 5.32 | 4.44 | 3.25 |
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 280 | 332 | 258 | 160 | 58.8 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 4.41 | 9.29 | 21.4 | 28.8 | 13.1 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 5.28 | 10.9 | 23 | 30.1 | 13.9 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 274 | 321 | 235 | 130 | 44.8 |
| Total Liabilities & Shareholders' Equity | 280 | 332 | 258 | 160 | 58.8 |
| Total Common Shares Outstanding |